Skip to main content
Fig. 2 | Trials

Fig. 2

From: Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

Fig. 2

Adaptive design for the efficacy of baricitinib-treated patients. aIncludes a minimum of 10 MTX-refractory/intolerant patients. bAll MTX-refractory/intolerant patients, naïve to biologics. MTX, methotrexate

Back to article page

Trials

ISSN: 1745-6215